Search

Your search keyword '"Denkert, C."' showing total 222 results

Search Constraints

Start Over You searched for: Author "Denkert, C." Remove constraint Author: "Denkert, C." Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
222 results on '"Denkert, C."'

Search Results

2. Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

4. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

5. Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023

6. ESMO Expert Consensus Statements on the management of breast cancer during pregnancy (PrBC)

8. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer

11. A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)

19. 99P Exploratory analysis of differential gene expression (DGE) and non-negative matrix factorisation (NMF) clustering in KATHERINE: Adjuvant trastuzumab emtansine (T-DM1) vs trastuzumab (H) in patients with HER2-positive residual invasive breast cancer after neoadjuvant treatment (NAT)

20. 208P Clinical characteristics and prognostic factors in patients with breast cancer and leptomeningeal metastases: A subanalysis of the German brain metastases in breast cancer registry (BMBC)

21. 129P Impact of TROP-2 and its cellular localization on prognosis of breast cancer in the GAIN cohort

22. 167P Deep learning-based whole slide image analysis to predict sentinel node status in the INSEMA cohort

23. P125 Neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy followed by adjuvant pembrolizumab vs placebo for early TNBC: surgical outcomes from the phase 3 KEYNOTE-522 study

25. Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response

28. Long-term survival of HER2-positive breast cancer patients with brain metastases: subanalysis of the BMBC Registry

29. 168P Long-term survival of a randomised, open-label, phase II study comparing the efficacy and safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)

30. 68MO Generalization of a deep learning model for HER2 status predictions on H&E-stained whole slide images derived from 3 neoadjuvant clinical studies

31. 269P Long-term survival of HER2-positive breast cancer patients with brain metastases: Subanalysis of the BMBC registry

32. 135MO HRQoL with neoadjuvant pembrolizumab + chemotherapy vs placebo + chemotherapy, followed by adjuvant pembrolizumab vs placebo for early-stage TNBC: Results from KEYNOTE-522

33. 200TiP A randomized, open-label, phase II trial comparing neoadjuvant trastuzumab, pertuzumab and endocrine therapy +/- the PI3K inhibitor inavolisib in patients (pts) with HER2+/HR+, PIK3CA mutant early breast cancer (BC)- GeparPiPPa

34. 151P Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts

35. Corrigendum to “A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study”

36. Eine mdm2 Genamplifikation ist mit Progression und Metastasierung des luminalen Mammakarzinoms im humanisierten Tumormausmodell (hPDX) assoziiert, sowie mit einem ungünstigen klinischen Verlauf der Erkrankung

37. Long-term survival of breast cancer patients with brain metastases: subanalysis of the BMBC Registry

38. 170P Long-term survival of breast cancer patients with brain metastases: Subanalysis of the BMBC registry

39. 58O Safety interim analysis (SIA) of the phase III postneoadjuvant SASCIA study evaluating sacituzumab govitecan (SG) in patients with primary HER2-negative breast cancer (BC) at high relapse risk after neoadjuvant treatment

40. 24P Intermediate biopsies during neoadjuvant chemotherapy for breast cancer to predict patient outcome

41. 94P Patient quality of life (QoL) from the GeparX trial on the addition of denosumab (Dmab) added to two different nab-paclitaxel (nP) regimens as neoadjuvant chemotherapy (NACT) in primary breast cancer (BC)

42. 12P Prevalence of functional and genomic homologous recombination deficiency (HRD) in germline RAD51C/D patients

43. 60MO Ovarian function in young patients (pts) treated with postneoadjuvant palbociclib (PAL) and endocrine therapy (ET) for hormone receptor (HR)-positive, HER2-negative early breast cancer (BC): Explorative analysis in Penelope-B

48. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

49. PREcoopERA Window-of-Opportunity trial of giredestrant+/- triptorelin vs. anastrozole+triptorelin in premenopausal patients with ER-positive/HER2-negative early breast cancer.

Catalog

Books, media, physical & digital resources